National and Kapodistrian University of Athens
Έκφραση των υποδοχέων σωματοστατίνης 1-5 (SSTR1-5) σε λειομύωμα ανθρώπινης μήτρας και σε παρακείμενους ιστούς μυομητρίου κατά τη διάρκεια του έμμηνου κύκλου, κατόπιν θεραπείας με LHRH-A και εμμηνοπαυσιακά
Abstract
dc:descriptionSomatostatin is a peptide that, via the stimulation of five different receptor subtypes (SSTR1-5), participates in various biological regulatory systems that play an important and diverse role in the pathophysiology of neoplasms. Despite the important progress in elucidating the risk factors, as well as various hormonal and growth mediators that facilitate the development and growth of leiomyomas, knowledge with regards to the molecular characteristics of these neoplasms remains scarce. In addition, as there is still no effective long-term medical therapy for the treatment of leiomyomas, there is an urgent need to elucidate the molecular receptors and signaling pathways which may be utilized for the targeted treatment of these neoplasms. Recent studies in small cohorts of patients have shown significant reduction in leiomyoma volume as well as symptomatic relief following treatment with somatostatin agonists. The present study evaluated, for the first time, the expression of all SSTR subtypes in leiomyomas and adjacent myometrium. Tissue samples were collected from 82 patients who underwent hysterectomy for the treatment of symptomatic leiomyomas. Patients were stratified according to menstrual cycle phase (proliferative phase, secretory phase as well as postmenopausal patients) and whether or not they had been pre-treated with luteinizing hormone-releasing hormone (LHRH) agonists. Following sample analysis for the expression of specific SSTR subtype mRNA transcripts, it was determined that all SSTR subtypes may be expressed in both leiomyomas and myometrium, with differing expression patterns. The SSTR2A and SSTR5 subtypes showed the highest expression rates and transcript levels in both leiomyomas and myometrium. The highest SSTR2A expression levels were observed in leiomyoma tissues from women during the secretory phase of the menstrual cycle. The SSTR1 subtype also showed very high expression patterns, which however were significantly reduced in leiomyoma samples from postmenopausal women, as well as in women pre-treated with LHRH agonists. The SSTR3 subtype demonstrated moderate expression in both leiomyoma and myometrium samples, while SSTR4 and the SSTR2B isoform of SSTR2 showed the lowest expression levels. The present study verified the presence of SSTR subtypes in all leiomyomas tested. The SSTR expression patterns indicated by this study’s findings may guide development of targeted clinical protocols for the diagnosis and treatment of leiomyomas.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Msaouel, Pavlos
- Μσάουελ, Παύλος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27364